Pretibial epidermolysis bullosa: genetic linkage to COL7A1 and identification of a glycine-to-cysteine substitution in the triple-helical domain of type VII collagen

Angela M. Cristiano, Julia Yu-Yun Lee, Wei J. Chen, Sal LaForgia and Jouni Uitto

Departments of 1Dermatology, and 2Biochemistry and Molecular Biology, Jefferson Medical College, and Section of Molecular Dermatology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA, 3Department of Dermatology, National Cheng-Kung University Medical Center, Taiwan and 4Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan, ROC.

Received March 31, 1995; Revised and Accepted June 5, 1995

INTRODUCTION

Pretibial epidermolysis bullosa (PEB) is a rare variant of dominant dystrophic EB (DDEB) in which recurrent blistering with scarring predominantly involves the pretibial skin. Although blistering appears to be localized clinically, electron microscopy of the dermal-epidermal junction in patients with PEB reveals anchoring fibril abnormalities that are not restricted to the predilection sites. Furthermore, PEB cannot be distinguished from the generalized (Cockayne-Touraine and Pasini) types of DDEB on the basis of anchoring fibril morphology alone. The generalized forms of DDEB have been linked to the type VII collagen gene (COL7A1) on chromosome 3p21. In this study, we sought to test the hypothesis that mutations underlying PEB also reside in COL7A1.

RESULTS

Clinical and genetic features

The family subjected to study consisted of 12 affected living individuals in three generations (Fig. 1). The clinical phenotype was characterized by pretibial blisters which developed into prurigo-like hyperkeratotic lesions (Fig. 2). Strikingly, the lesions were present predominantly on the pretibial areas, sparing the knees and other parts of the skin (Fig. 2). Other clinical features included nail dystrophy, albopapuloid skin lesions, and hypertrophic scars without pretibial predominance. There was considerable inter-individual variability which has been detailed in a previous report (2) (see Clinical description...
Figure 1. Pedigree of the family with pretibial epidermolysis bullosa (PEB). Haplotype analysis was performed on 12 affected and two unaffected family members representing three generations, and the genotypes were established with markers shown on the right of generation V. The anonymous markers D3S1029, D3S1235, and D3S1573 are microsatellites flanking the COL7A1 locus at 3p21. The marker D3S1029 is telomeric, while the exact relative position of the two other microsatellites with respect to the COL7A1 locus has not been established. The COL7A1/PvuII polymorphism represents an intragenic silent single-base substitution. COL7A1/G2623C is the mutation co-segregating with the clinical phenotype. Co-inheritance of the clinical phenotype with the boxed haplotype is noted, with $Z = 3.61$ at $\theta = 0$.

Genetic linkage analysis

Recent cloning of the human type VII collagen gene (COL7A1) (12,13) and its mapping to 3p21(9,10) allowed us to perform genetic linkage analyses in families with dystrophic EB. In this study, an intragenic PvuII polymorphism was initially used for linkage analysis (5,14). This marker was partially informative in this family yielding a maximum LOD score ($Z$) of 1.75 at $\theta = 0$ (Table 1). Subsequently, three flanking markers (D3S1029, D3S1235, and D3S1573) (15) were partially informative with no recombination events (Table 1). The data were consistent with genetic linkage of the PEB locus to COL7A1 in this family. This conclusion was subsequently verified by demonstration of a single base substitution in COL7A1 (see below), and genetic linkage of the mutation with the PEB phenotype resulted in a maximum LOD score ($Z$) = 3.61 at $\theta = 0$. Several three- or four-point linkage analyses (assuming the marker intervals being known; see Table 1) were performed with the LINKMAP program. Once the mutation was included in the analyses, the maximum LOD scores between the PEB and the mutation as well as the four informative markers were very similar, ranging from 3.60 to 3.61. No recombination between any of the markers and the mutation was observed.

Mutation identification

During verification of a different missense mutation in one allele in COL7A1 of an unrelated proband with recessive DEB (R2622Q) which resulted in loss of an SmaI site (CCCGGG to CCCAGG), two affected individuals in the family with PEB reported in this study also showed a similar restriction digestion pattern. To examine the basis of this restriction enzyme site change, exons 105 and 106 of COL7A1 were PCR amplified from the flanking intronic sequences, and the product was subjected to direct nucleotide sequencing. The results revealed a G-to-T transversion in nt position 7867 of the type VII collagen cDNA (Fig. 3). This substitution resulted in a change of a glycine (QGC) to a cysteine (JGC) codon, and the mutation was designated as G2623C. As indicated above, this mutation resulted in a loss of a SmaI restriction enzyme site (CCCGGG to CCCGGT), and the inheritance of the mutation in the family was confirmed at the DNA level by digestion with this restriction enzyme (Fig. 3). Examination of 78 unrelated individuals with different forms of EB, and 34
Table 1. Two-point LOD scores for the pretibial variant of dominant dystrophic epidermolysis bullosa and markers on chromosome 3

<table>
<thead>
<tr>
<th>Marker</th>
<th>0</th>
<th>0.01</th>
<th>0.05</th>
<th>0.1</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3S1029</td>
<td>0.89</td>
<td>0.88</td>
<td>0.81</td>
<td>0.71</td>
<td>0.51</td>
<td>0.29</td>
<td>0.09</td>
</tr>
<tr>
<td>D3S1235</td>
<td>1.87</td>
<td>1.82</td>
<td>1.60</td>
<td>1.32</td>
<td>0.71</td>
<td>0.06</td>
<td>0.42</td>
</tr>
<tr>
<td>D3S1573</td>
<td>1.51</td>
<td>1.48</td>
<td>1.35</td>
<td>1.19</td>
<td>0.86</td>
<td>0.53</td>
<td>0.23</td>
</tr>
<tr>
<td>Pvull</td>
<td>1.75</td>
<td>1.72</td>
<td>1.57</td>
<td>1.39</td>
<td>1.01</td>
<td>0.63</td>
<td>0.30</td>
</tr>
<tr>
<td>G2623C</td>
<td>3.61</td>
<td>3.55</td>
<td>3.32</td>
<td>3.01</td>
<td>2.35</td>
<td>1.61</td>
<td>0.80</td>
</tr>
</tbody>
</table>

The distances (bp) between the markers were set at: (telomere)-D3S1029-(0.005)-D3S1235-(0.003)-D3S1573-(0.003)-Pvull-(0.003)-G2623C-(0.006)-(centromere)

**DISCUSSION**

In this study, we have demonstrated that a single base change resulting in a glycine-to-cysteine substitution in the triple helical domain of type VII collagen co-segregates with the phenotype in a family with a dominantly inherited form of DEB, with unique clinical features. Specifically, these patients demonstrate localized, predominantly pretibial blister formation, with nail dystrophy and hypertrophic scarring. Thus, the clinical phenotype is clearly distinct from the more generalized forms of DDEB, the Cockayne-Touraine and Pasini types (1). It should be noted, however, that the ultrastructural features of the dermal–epidermal junction of the skin in all three forms of DDEB, i.e., sub-basal lamina tissue separation and paucity of anchoring fibrils, are indistinguishable. Furthermore, all three types of DDEB are allelic, since we have previously demonstrated specific mutations in COL7A1 in three different families with dominantly inherited DEB with features of the Cockayne-Touraine or Pasini type (16–18). It should be noted that another dominantly inherited clinical variant of dystrophic EB, the Bart syndrome, has also been linked to the COL7A1 locus (19). Thus, four different subtypes of DDEB studied thus far appear to be due to mutations in the COL7A1 gene.

The mutation disclosed in the family with PEB, G2623C, replaces a glycine residue in a collagenous domain consisting

![Figure 2](image-url) Clinical presentation of a family member with PEB (V-8 in Fig. 1). Note the presence of prurigo-like cutaneous lesions with excoriation, largely limited to the pretibial area.

![Figure 3](image-url) Mutation detection in the family with PEB. (A) Digestion of PCR products representing exons 105–106 of COL7A1 with Smal from representative individuals of the family shown in Fig. 1. The nucleotide substitution (see below) resulted in the loss of a naturally occurring Smal site. Thus, in normal individuals, the 457 bp PCR product is completely digested to 326 and 131 bp fragments. In the affected individuals, heterozygous for the nucleotide substitution, an undigested 457 bp band, in addition to the digestion fragments, is noted. (B) Sequencing of the PCR product containing the mutation reveals the presence of a T, instead of a G noted in the normal allele. This nucleotide substitution results in glycine (GGC) substitution by a cysteine (TGC); this mutation is designated as G2326C.
of 74 uninterrupted Gly-X-Y repeats. This mutation creates a new cysteine residue 11 amino acids upstream from a conserved cysteine residue in COL7A1 (C2634), which is thought to play a critical role in intermolecular assembly of type VII collagen molecules into anchoring fibrils (20). The previously disclosed dominant dystrophic EB mutations consist of glycine substitutions (G2040S, G2043R and G2351R) (16–18) which reside upstream from the mutation described in this family with PEB. All these substitutions affect different glycine residues in the collagenous sequence of type VII collagen.

The new cysteine residue generated by the mutation in the PEB family could potentially result in the formation of an abnormal disulfide bond. Alternatively, the substitution of a glycine in the collagenous (Gly-X-Y)_n sequences could destabilize the critical triple-helical conformation of the collagenous domain. Glycine substitutions in other collagen genes have been shown to be the basis for a variety of heritable connective tissue diseases. Specifically, mutations in collagens type I, II, III, and IV, largely consisting of glycine substitutions within the triple helical domain of the protein, have been shown to be the basis of osteogenesis imperfecta, chondrodysplasias, Ehlers-Danlos syndrome IV, and Alport syndrome, respectively (21–23). Thus, the likely explanation for the fragility of the skin in the PEB family is abnormalities in anchoring fibrils due to destabilization of the type VII collagen triple helical domain as a result of glycine substitution. It should be noted that since type VII collagen is a homotrimer of three identical α1(VII) chains, one out of eight molecules will consist of three normal polypeptides, assuming equal expression of both alleles at the protein level (24). Thus, one would expect that a small number of anchoring fibrils can be assembled from these normal molecules, an observation consistent with ultrastructural demonstration of the presence of a few, often thin anchoring fibrils. The presence of some anchoring fibrils may explain the milder phenotype of DDEB, in contrast to the extreme fragility of the skin observed in the recessively inherited forms, such as the Hallepoue-Siemens type of DEB, which demonstrate a complete absence of anchoring fibrils in most cases due to the presence of premature termination codons in both COL7A1 alleles (25–28).

MATERIALS AND METHODS

Clinical description

The family under study was Family C from a five-generation kindred of PEB reported previously (2). The proband was a 47 year old Taiwanese woman (IV-8, Fig. 1). She presented with a history of blistering over the pretibial areas resulting in hypertrophic scars and milia. Her big toe nails were lost (IV-8, Fig. 1). She presented with a history of blistering over the pretibial area, and Taiwan National Science Council Grant 82-0412-B006-093-M02.

Reference


ACKNOWLEDGEMENTS

We appreciate the excellent technical assistance of Yili Xu and Xin Zhang, and thank Tamara Alexander and Eileen O'Shaughnessy for preparation of the manuscript. We appreciate the interest and participation of the family members in this study. This work was supported in part by USPS, NIH Grant PO1-AR38923, the Dermatology Foundation, the March of Dimes Birth Defects Foundation, the Lin Roug-San Culture and Public Welfare Foundation, and Taiwan National Science Council Grant 82-0412-B006-093-M02.


